TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Drug Selegiline; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: matching placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): Drug Selegiline | Intervention Type: OTHER; Name: matching placebo; Assigned to Arm(s): Matching placebo
C: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment
B: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline (CP-526,555) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo Arm | Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): Treatment Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
B: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to 1) evaluate the safety and efficacy of two doses of bupropion SR (150mg/day and 300mg/day) when compared to placebo, as an aid to smoking cessation in adolescents and 2) to examine which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
B: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
C: Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse
Brief Summary: This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).


Options:
A: Arm Label: ADV-TK/GCV; Type: EXPERIMENTAL; Interventions: Biological: ADV-TK/GCV | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: systemic chemotherapy | Intervention Type: BIOLOGICAL; Name: ADV-TK/GCV; Assigned to Arm(s): ADV-TK/GCV | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Control group | Intervention Type: DRUG; Name: systemic chemotherapy; Assigned to Arm(s): Control group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: irinotecan | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2
C: Arm Label: Carbon Ion Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Carbon Ion Radiotherapy | Arm Label: Standard Treatment: Fractionated Stereotacitc Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Fractionated Stereotactic Radiotherapy (FSRT) | Intervention Type: RADIATION; Name: Carbon Ion Radiotherapy; Assigned to Arm(s): Carbon Ion Radiotherapy | Intervention Type: RADIATION; Name: Fractionated Stereotactic Radiotherapy (FSRT); Assigned to Arm(s): Standard Treatment: Fractionated Stereotacitc Radiotherapy
D: Arm Label: Arm A: AA-PET based target volume delineation; Type: EXPERIMENTAL; Interventions: Radiation: Radiation Therapy | Arm Label: Arm B: T1Gd-MRI based target volume delineation; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiation Therapy | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): Arm A: AA-PET based target volume delineation | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): Arm B: T1Gd-MRI based target volume delineation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse
Brief Summary: This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab, Drug: irinotecan | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): 2
B: Arm Label: Bevacizumab + RT + Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temozolomide, Radiation: Radiation therapy | Arm Label: Placebo + RT + Temozolomide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiation therapy, Drug: Placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + RT + Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: RADIATION; Name: Radiation therapy; Assigned to Arm(s): Bevacizumab + RT + Temozolomide, Placebo + RT + Temozolomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + RT + Temozolomide
C: Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: Cilengitide + Temozolomide + Radiotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cilengitide, Drug: Temozolomide, Radiation: Radiotherapy | Arm Label: Temozolomide + Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Radiation: Radiotherapy | Intervention Type: DRUG; Name: Cilengitide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Cilengitide + Temozolomide + Radiotherapy, Temozolomide + Radiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
C: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil
D: Arm Label: OMEGA-3; Type: ACTIVE_COMPARATOR; Interventions: Drug: OMEGA-3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo soybean oil | Intervention Type: DRUG; Name: OMEGA-3; Assigned to Arm(s): OMEGA-3 | Intervention Type: DRUG; Name: Placebo soybean oil; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
C: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A
D: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
C: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet
D: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration
Brief Summary: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid \[DHA\] + eicosapentaenoic acid \[EPA\]), or both might further reduce this risk. AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA + EPA, or lutein + zeaxanthin and DHA + EPA to the AREDS formulation might further reduce the risk of progression to advanced AMD. A secondary goal was to test the effects of eliminating beta carotene and reducing zinc dose in the AREDS formulation.


Options:
A: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
B: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Beta-Carotene; Assigned to Arm(s): N/A
C: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2

Answer: A